Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report

Monoclonal antibodies blocking PD-1 and CTLA-4 immunological checkpoints lead to durable tumor responses in a considerable number of advanced melanoma patients. Besides their anti-neoplastic efficacy, these immune checkpoint inhibitors cause a wide range of immune-related adverse events (irAEs), oft...

Full description

Bibliographic Details
Main Authors: Johanna Matull, Elisabeth Livingstone, Axel Wetter, Lisa Zimmer, Anne Zaremba, Harald Lahner, Dirk Schadendorf, Selma Ugurel
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
checkpoint inhibitors
melanoma
immune-related adverse events
therapy discontinuation
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.592609/full

Similar Items

Similar Items